Susan Murry
Nurse Practitioner · Bryan, OHNPI 1144333808
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,650 of the $41,464 with a category attached, or 71.5%. Novo Nordisk accounts for 65.0% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $14,351 and has fallen 77.1% since, to $3,287 in 2025. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 445 payments — averaging $93.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$27K
- Abbott$9K
- Sanofi$888
- Dexcom, Inc.$835
- Lilly USA, LLC$735
- Corcept Therapeutics$621
- plus $2K from 12 others
What the payments were for
- Consulting fees$2,5286%
- Speaking & faculty fees$29,65072%
- Travel & lodging$2,5756%
- Food & beverage$6,68416%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 131 | $26,965 |
| Abbott | 41 | $8,964 |
| Sanofi | 1 | $888 |
| Dexcom, Inc. | 65 | $835 |
| Lilly USA, LLC | 71 | $735 |
| Corcept Therapeutics | 18 | $621 |
| Boehringer Ingelheim | 31 | $577 |
| Sanofi-aventis U.S. LLC | 21 | $438 |
| Bayer | 26 | $408 |
| AstraZeneca | 17 | $394 |
| Tandem Diabetes Care, Inc. | 5 | $189 |
| AbbVie | 3 | $176 |
| Merck | 7 | $119 |
| Inspire Medical Systems, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Novartis | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $28 |
| Medtronic | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$19,627
- FREESTYLE LIBRE 3$8,351
- Ozempic$3,658
- Saxenda$1,140
- TZIELD$993
- Korlym$217
- BREZTRI$123
- t:slim X2 Insulin Pump with Control-IQ$116
How this compares
$41,464 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 356 | $573,144 |
| Tresiba Flextouch U-200Insulin Degludec | 281 | $475,087 |
| JardianceEmpagliflozin | 343 | $402,338 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 262 | $383,665 |
| MounjaroTirzepatide | 243 | $365,389 |
| TrulicityDulaglutide | 173 | $296,888 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 163 | $182,898 |
| FarxigaDapagliflozin Propanediol | 121 | $133,501 |
| Tresiba Flextouch U-100Insulin Degludec | 155 | $128,228 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 52 | $119,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $74,954 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $38,670 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 42 | $34,817 |
| Novolog FlexpenInsulin Aspart | 73 | $28,962 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $26,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $735 | $668,720439 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp | $26,965 | $628,255400 claims |
| Boehringer IngelheimJardiance | $577 | $402,338343 claims |
| AstraZenecaFarxiga | $394 | $133,501121 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $438 | $38,67026 claims |
| MerckJanuvia, Janumet | $119 | $30,89742 claims |
| BayerKerendia | $408 | $23,41028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Bryan
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.